We are delighted to welcome you to our latest issue of EMJ Nephrology. Sharing key updates in the field in the form of reviews and research articles, our latest release features insights into COVID-19-associated nephropathy, diabetic kidney disease, and perspectives on the use of sodium-glucose co-transporter inhibitors in kidney disease. Also included is a comprehensive review of the 59th European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) 2022 Congress, with late breaking abstract reviews written by the presenters themselves.
Latest articlesAll articles
Hypertension in Patients Receiving Dialysis: A Review of the Current Clinical Approach
Hypertension is a common complication in advanced chronic kidney disease (CKD), occurring in approximately 80–85% of patients. Blood pressure (BP) control is suboptimal in the majority of these patients. The link between uncontrolled hypertension and mortality among patients with end-stage kidney disease (ESKD) is well documented.
Prevalence of SARS-CoV-2 Cellular and Humoral Immunity Amongst Patients on Dialysis After the First Vaccination Campaign
Global immunisation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the standard-of-care in preventing COVID-19 and, in the absence of a specific antiviral therapy, the only effective action against this pandemic.
Infographic: Advancing Therapeutic Goals in IgA Nephropathy
This infographic explores the epidemiology, burden, and unmet need in IgA nephropathy (IgAN). Delving into the pathophysiology of IgAN, the infographic breaks down the different aspects of the kidney that are impacted by the inflammatory mediators endothelin-1 and angiotensin II.